Is It PRIME Time for Biparametric Magnetic Resonance Imaging in Prostate Cancer Diagnosis?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 35277288.
- Also identified by DOI 10.1016/j.eururo.2022.02.021.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The PRIME (PRostate Imaging using Mri +/- contrast Enhancement) study is evaluating whether quicker, cheaper, and less invasive biparametric magnetic resonance imaging (bpMRI) is noninferior to multiparametric MRI in diagnosing clinically significant prostate cancer (PCa). If the study results confirm that bpMRI is not inferior, it could become the new standard of care for PCa diagnosis and streamline the diagnosis pathway so that all men who need MRI have access to this diagnostic tool.
Medical subject headings
- Multiparametric Magnetic Resonance Imaging
- Prostatic Neoplasms